Ulcerative Colitis and Transplantation Pipeline Review, H1 2013

Global Markets Direct’s, ‘Ulcerative Colitis and Transplantation – Pipeline Review, H1 2013′, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Ulcerative Colitis and Transplantation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ulcerative Colitis and Transplantation. Ulcerative Colitis and Transplantation – Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- A snapshot of the global therapeutic scenario for Ulcerative Colitis and Transplantation.
- A review of the Ulcerative Colitis and Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Ulcerative Colitis and Transplantation pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Get Report Details of Transplantation Pipeline Review @ http://www.rnrmarketresearch.com/transplantation-pipeline-review-h1-2013-market-report.html

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Ulcerative Colitis and Transplantation.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Ulcerative Colitis and Transplantation pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Get Report Details of Ulcerative Colitis Pipeline Review @ http://www.rnrmarketresearch.com/ulcerative-colitis-pipeline-review-h1-2013-market-report.html

Table of Content

Table of Contents 2
List of Tables 5
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Ulcerative Colitis and Transplantation Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Ulcerative Colitis and Transplantation 10
Ulcerative Colitis and Transplantation Therapeutics under Development by Companies 12
Ulcerative Colitis and Transplantation Therapeutics under Investigation by Universities/Institutes 17
Late Stage Products 19
Comparative Analysis 19
Mid Clinical Stage Products 20
Comparative Analysis 20
Early Clinical Stage Products 21
Comparative Analysis 21
Discovery and Pre-Clinical Stage Products 22
Comparative Analysis 22
Ulcerative Colitis and Transplantation Therapeutics - Products under Development by Companies 23
Ulcerative Colitis and Transplantation Therapeutics - Products under Investigation by Universities/Institutes 28
Companies Involved in Ulcerative Colitis and Transplantation Therapeutics Development 29
Kyowa Hakko Kirin Co., Ltd. 29
Athersys, Inc. 30
GlaxoSmithKline plc 31
AbGenomics International, Inc. 32
Emergent BioSolutions Inc. 33
Albany Molecular Research, Inc. 34
BioLineRx, Ltd. 35
Astellas Pharma Inc. 36
ViroPharma Incorporated 37
Genmab A/S 38
Exelixis, Inc. 39
Celldex Therapeutics, Inc. 40
Clinuvel Pharmaceuticals Limited 41
NeoStem, Inc. 42
Synta Pharmaceuticals Corp. 43
Cellerant Therapeutics, Inc. 44
University of Erlangen-Nurnberg 45
Digna Biotech, S.L. 46
Viron Therapeutics, Inc. 47
Wellstat Therapeutics Corporation 48
Argos Therapeutics, Inc. 49
ApoImmune, Inc. 50
Recoly N.V. 51
TetraLogic Pharmaceuticals 52
Fresenius Biotech GmbH 53
NovImmune SA 54
TcL Pharma SAS 55
Omeros Corporation 56
Trillium Therapeutics Inc. 57
iBio, Inc. 58
Kiadis Pharma B.V. 59
Bellicum Pharmaceuticals, Inc. 60
Sirnaomics, Inc. 61
USV Limited. 62
Limerick BioPharma, Inc. 63
KYORIN Pharmaceutical Co., Ltd. 64
Tolera Therapeutics, Inc. 65
Medistem, Inc. 66
Medestea Research & Production S.p.A. 67
TikoMed AB 68
Dompe Farmaceutici S.p.A. 69
AIMM Therapeutics B.V. 70
Amplimmune, Inc. 71
Bio Sidus S.A. 72
Neumedicines Inc. 73
CellAct Pharma GmbH 74
Immune Technologies and Medicine 75
Sigmoid Pharma. 76
Ulcerative Colitis and Transplantation - Therapeutics Assessment 77
Assessment by Monotherapy Products 77
Assessment by Combination Products 78
Assessment by Route of Administration 79
Assessment by Molecule Type 81
Drug Profiles 84
ASKP-1240 - Drug Profile 84
MultiStem - Drug Profile 85
PN-951 - Drug Profile 87
CRACM Channel Inhibitors - Drug Profile 88

For more details contact Mr. Priyank Tiwari: sales@rnrmarketresearch.com / +18883915441

Website: http://www.rnrmarketresearch.com/